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Introduction {#cam41067-sec-0001}
============

Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed cancers and the leading causes of cancer death worldwide. As a high incidence area of HCC, China accounts for about 50% of the total number of cases and deaths worldwide [1](#cam41067-bib-0001){ref-type="ref"}, [2](#cam41067-bib-0002){ref-type="ref"}. In 2015, it had an estimated of 466,100 and 422,100 patients is diagnosed and die of HCC in China, respectively[1](#cam41067-bib-0001){ref-type="ref"}, which makes HCC a major public health concern in China. For the past decade, cancer staging systems, such as the Barcelona Clinic Liver Cancer (BCLC) staging system and Cancer of the Liver Italian Program (CLIP) score, have been established for the prognosis assessment by using clinical variables mainly including tumor size, number of primary tumors, portal vein tumor thrombosis, and inflammatory degree [3](#cam41067-bib-0003){ref-type="ref"}, [4](#cam41067-bib-0004){ref-type="ref"}. But none of these systems has been universally adopted by clinicians. Many novel molecular biomarkers, such as Alpha‐fetoprotein, circulating tumor cells and circulating microRNAs, have been also applied to predict HCC progression [5](#cam41067-bib-0005){ref-type="ref"}. However, limitations of low sensitivity and specificity are still associated with these biomarkers when used in disease staging [5](#cam41067-bib-0005){ref-type="ref"}. Long‐term outcome prediction for HCC patients remains unfavorable [6](#cam41067-bib-0006){ref-type="ref"}, [7](#cam41067-bib-0007){ref-type="ref"}, which hampers the development of personalized clinical assessment for HCC patients and calls for identifying additional, more discriminant prognostic indicators.

In recent years, the development of human genome research has been witnessed much success in mining cancer‐related germline genetic variants, especially single nucleotide polymorphisms (SNPs). The current advance in genome‐wide association studies (GWASs) has led to the identification of several SNPs that are associated with HCC risk [8](#cam41067-bib-0008){ref-type="ref"}, [9](#cam41067-bib-0009){ref-type="ref"}, [10](#cam41067-bib-0010){ref-type="ref"}, [11](#cam41067-bib-0011){ref-type="ref"}. Additionally, a series of studies also reported that the HCC patients survival was associated with SNPs in genes functioning in pivotal biological pathways or processes, such as cytokine genes [12](#cam41067-bib-0012){ref-type="ref"}, [13](#cam41067-bib-0013){ref-type="ref"}, telomere maintenance genes [14](#cam41067-bib-0014){ref-type="ref"}, DNA repair genes [15](#cam41067-bib-0015){ref-type="ref"}, Wnt/β‐catenin pathway genes [16](#cam41067-bib-0016){ref-type="ref"}. These pieces of evidence demonstrate that genetic variants act as indicators of different processes of HCC and may provide further information beyond current clinical staging and pathologic prognostic assessments.

The cell cycle is a set of organized and monitored events responsible for proper cell division into two daughter cells, which includes four traditional subdivision phases (i.e., G1, S, G2 and M) and is controlled by the signaling pathway comprising genes encoding cyclins, cyclin‐dependent kinases, and cyclin kinase inhibitors as well as the related regulators (e.g., MYC) [17](#cam41067-bib-0017){ref-type="ref"}, [18](#cam41067-bib-0018){ref-type="ref"}, [19](#cam41067-bib-0019){ref-type="ref"}. Disruption of the cell cycle pathway can result in cell cycle arrest and has previously been related to prognosis of human cancers [20](#cam41067-bib-0020){ref-type="ref"}, [21](#cam41067-bib-0021){ref-type="ref"}. For example, CDKN2A and RB1 expression levels have been associated with survival of patients with advanced‐stage ovarian cancer [22](#cam41067-bib-0022){ref-type="ref"}. In addition, several studies have also demonstrated that aberrant expression of cell cycle pathway genes, including cyclin (A, D1 and E), CDC2, p27 and p21, is associated with prognosis for patients with HCC [23](#cam41067-bib-0023){ref-type="ref"}, [24](#cam41067-bib-0024){ref-type="ref"}, [25](#cam41067-bib-0025){ref-type="ref"}, [26](#cam41067-bib-0026){ref-type="ref"}, [27](#cam41067-bib-0027){ref-type="ref"}.

We have previously investigated the association of genetic variants in cell cycle pathway genes with susceptibility to HCC and found that SNPs in *MCM4*,*CHEK1* and *KAT2B* were associated with HCC risk [28](#cam41067-bib-0028){ref-type="ref"}. There are additional studies demonstrating the associations between genetic variants of cell cycle pathway genes and survival of cancers of the ovaries, oral cavity and lung [29](#cam41067-bib-0029){ref-type="ref"}, [30](#cam41067-bib-0030){ref-type="ref"}, [31](#cam41067-bib-0031){ref-type="ref"}. However, the associations between genetic variants of cell cycle pathway genes and prognosis of HCC remain largely unknown. In this study, we hypothesized that genetic variants in cell cycle pathway genes are associated with survival of HCC patients. To test this hypothesis, we evaluated the associations of potential functional SNPs in 16 main cell cycle pathway genes (*CDC25C*,*CDC7*,*CDKN1A*,*CDKN2A*,*CHEK1*,*MCM4*,*MCM7*,*MYC*,*ORC6L*,*KAT2B*,*PLK1*,*RAD21*,*RBL2*,*SMAD3*,*TGFB3*, and *YWHAB*) with clinical outcomes of 271 HCC cases who had undergone radical surgery resection.

Materials and Methods {#cam41067-sec-0002}
=====================

Study population {#cam41067-sec-0003}
----------------

The patients were derived from our previously published case--control study [28](#cam41067-bib-0028){ref-type="ref"}. A total of 1127 patients with newly diagnosed and pathologically confirmed HCC were recruited consecutively between June 2007 and December 2013 from the First Affiliated Hospital and Affiliated Tumor Hospital of Guangxi Medical University. Among these patients, 271 undergone radical surgery resection with completed clinical information and long‐term follow‐up data for survival analysis. Clinical information (including age at diagnosis, sex, ethnicity, hepatitis B virus infection, smoking status, drinking status, capsule, portal vein tumor thrombosis, cirrhosis, and BCLC staging) was collected from medical records. Peripheral venous blood was collected in a vacuum EDTA anticoagulant tube from each participant. Genomic DNA was extracted using a standard phenol/chloroform extraction method and stored at −80°C. The study protocol was approved by the ethical committee of Guangxi Medical University, and a written informed consent was obtained from each of the participants.

Follow‐up {#cam41067-sec-0004}
---------

All of the patients were followed up to collect data on postoperative recurrence, distant metastasis and death condition through phone calls or the medical records. The endpoint was disease‐free survival (DFS). DFS was defined as the interval between the date of tumor resection and the date of the presence of relapse/metastasis/death or until the last follow‐up. Patients who were lost to follow‐up, who were alive at the last follow‐up and who did not have developed recurrence/metastasis were censored.

SNP selection and genotyping {#cam41067-sec-0005}
----------------------------

The methods of SNP selection and genotyping have been described previously [28](#cam41067-bib-0028){ref-type="ref"}. In brief, we found 3826 differential expressed genes by analysis of three HCC‐related genome expression microarrays (GSE14520, GSE25097, and GSE12941) from GEO database. After performing the gene ontology classification and pathway enrichment analysis by using blast2GO and DAVID (<https://david.ncifcrf.gov/>), we identified 40 cell cycle pathway genes involved in the cellular process. Considering the literature on these genes with cancer survival, we selected 16 genes (*CDC25C*,*CDC7*,*CDKN1A*,*CDKN2A*,*CHEK1*,*MCM4*,*MCM7*,*MYC*,*ORC6L*,*KAT2B*,*PLK1*,*RAD21*,*RBL2*,*SMAD3*,*TGFB3*, and *YWHAB*) for further analysis. The genotype information of the 16 genes were downloaded from Hapmap website (<http://hapmap.ncbi.nlm.nih.gov/>), and functional SNPs were selected using SNPinfo (<https://snpinfo.niehs.nih.gov/>) [32](#cam41067-bib-0032){ref-type="ref"}. Considering the minor allele frequency (MAF ≥ 0.05), linkage disequilibrium (LD, *r* ^2^ \> 0.8) and potential functions in transcription factor‐binding, microRNA‐binding and splicing sites, we finally included 24 SNPs with putative functions in this study (Table [1](#cam41067-tbl-0001){ref-type="table-wrap"}). Then, we performed the genotyping by using a MassARRAY system (Sequenom, San Diego, CA, USA) and a matrix‐assisted laser desorption ionization‐time of flight mass spectrometry method according to the manufacturer\'s instructions. All the primers for PCR were designed using the Assay Designer software package of the Sequenom system (San Diego, CA, USA).

###### 

SNPs selection and prediction function in SNPinfo

  Genes      SNP          CHR   Position    Allele[a](#cam41067-note-0005){ref-type="fn"}   MAF    Prediction function in SNPinfo[b](#cam41067-note-0006){ref-type="fn"}
  ---------- ------------ ----- ----------- ----------------------------------------------- ------ -----------------------------------------------------------------------
  *CDC25C*   rs3734166    5     137693222   A/G                                             0.42   Nonsynonymous variant
  *CDC7*     rs13447539   1     91758416    A/G                                             0.05   Splicing site and nonsynonymous variant
  *CDKN1A*   rs3176320    6     36754766    A/G                                             0.24   Transcription factor binding site
  *CDKN1A*   rs3176329    6     36755441    G/T                                             0.09   Transcription factor binding site
  *CDKN2A*   rs3088440    9     21958159    G/A                                             0.12   Transcription factor and microRNA‐binding site
  *CHEK1*    rs3731399    11    125002457   T/C                                             0.17   Transcription factor binding site
  *CHEK1*    rs515255     11    125002355   C/T                                             0.40   Transcription factor binding site
  *MCM4*     rs2305952    8     49037162    T/C                                             0.17   Transcription factor binding site
  *MCM7*     rs2070215    7     99534733    A/G                                             0.17   Splicing site and nonsynonymous variant
  *MCM7*     rs2261360    7     99530929    C/A                                             0.40   Transcription factor and microRNA‐binding site
  *MCM7*     rs4928       7     99528626    C/G                                             0.06   Splicing site
  *MYC*      rs4645948    8     128817680   C/T                                             0.13   Transcription factor binding site
  *ORC6L*    rs12596237   16    45284886    C/T                                             0.05   Transcription factor binding site
  *ORC6L*    rs33994299   16    45281099    T/C                                             0.06   Transcription factor binding site and splicing site
  *PCAF*     rs17006625   3     20136100    A/G                                             0.14   Splicing site and nonsynonymous variant
  *PCAF*     rs4858770    3     20169427    C/T                                             0.47   MicroRNA‐binding site
  *PLK1*     rs2230915    16    23608959    G/A                                             0.05   Splicing site and microRNA‐binding variant
  *RAD21*    rs16889105   8     117952045   A/G                                             0.40   Transcription factor and microRNA‐binding site
  *RAD21*    rs6987652    8     117951462   G/A                                             0.16   Transcription factor binding site
  *RBL2*     rs3929       16    52081809    G/C                                             0.21   MicroRNA‐binding site
  *SMAD3*    rs11556090   15    65273437    A/G                                             0.11   MicroRNA‐binding site
  *SMAD3*    rs8025774    15    65270330    C/T                                             0.50   MicroRNA‐binding site
  *TGFB3*    rs3917148    14    75516274    A/C                                             0.14   Transcription factor binding site
  *YWHAB*    rs2425675    20    42968348    G/A                                             0.18   Transcription factor binding site

SNP, single‐nucleotide polymorphism; CHR, chromosome; MAF, minor allele frequency.

Reference allele/minor allele.

SNPinfo: <https://snpinfo.niehs.nih.gov/>.
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Statistical methods {#cam41067-sec-0006}
-------------------

Cox proportional hazards regression analysis was conducted to assess the associations between SNPs and DRS in an additive model with adjustment for age at diagnosis, sex, ethnic, hepatitis B virus infection, smoking status, drinking status, capsule, portal vein tumor thrombosis, cirrhosis and BCLC staging. The false‐positive report probability (FPRP) approach was applied to correct for multiple comparisons [33](#cam41067-bib-0033){ref-type="ref"}. We assigned a prior probability of 0.1 to detect an HR of 2.0 for the adverse genotypes and alleles of SNPs with an elevated risk. Only the significant results with FPRP \<0.2 were considered noteworthy. The stepwise Cox model including noteworthy SNPs and clinical variables was conducted to choose independent predictive SNPs. Kaplan--Meier estimation of survival functions and Log‐rank tests were used to evaluate the single and combined effects of risk genotypes on DFS. The ROC curve was used to evaluate the performance of different prediction models, and Delong\'s test was conducted to compare the area under the curves (AUC) across different models [34](#cam41067-bib-0034){ref-type="ref"}. Finally, to assess the correlation between genetic variants and mRNA expression of the corresponding genes, the expression quantitative trait loci (eQTL) analysis was also performed using data from the GTEx project (<http://www.gtexportal.org/home/>) and the HapMap3 Project (Release version 2) by general linear regression model in additive genetic model [35](#cam41067-bib-0035){ref-type="ref"}, [36](#cam41067-bib-0036){ref-type="ref"}. All analyses were performed using SAS (version 9.1.3; SAS Institute, Cary, NC), unless otherwise specified.

Results {#cam41067-sec-0007}
=======

Basic characteristics of study populations {#cam41067-sec-0008}
------------------------------------------

The details of clinical information about age at diagnosis, sex, ethnicity, hepatitis B virus infection, smoking status, drinking status, capsule, portal vein tumor thrombosis, cirrhosis status, BCLC staging and survival outcomes are showed in Table [2](#cam41067-tbl-0002){ref-type="table-wrap"}. There were 271 cases of staging 0‐C (BCLC staging) who had undergone radical surgery resection with a median follow‐up time of 19.0 months. At the time of analysis, 185 (68.3%) patients reached the DFS endpoint. The median DFS time was 20.3 months and 1, 3 and 5‐year survival rate were 55.4%, 40.2%, and 28.9%, respectively. Univariate analysis indicated that only portal vein tumor thrombosis, cirrhosis, and BCLC staging were significantly associated with HCC DFS (*P *=* *0.007, 0.030 and 0.004, respectively).

###### 

Association between characteristic factors and HCC DFS by univariate Cox proportional hazards regression model

  Factors                        Patients   Event (%)[a](#cam41067-note-0008){ref-type="fn"}   HR (95% CI)         *P*
  ------------------------------ ---------- -------------------------------------------------- ------------------- -------
  Sex                                                                                                              
  Female                         24         19 (79.2)                                          1.00                
  Male                           247        166 (67.2)                                         0.99 (0.62--1.59)   0.964
  Age                                                                                                              
  ≤50                            164        112 (68.3)                                         1.00                
  \>50                           107        73 (68.2)                                          0.88 (0.66--1.18)   0.403
  Ethnicity                                                                                                        
  Han                            175        125 (71.4)                                         1.00                
  Zhuang/others                  96         60 (62.5)                                          0.85 (0.62--1.15)   0.285
  HBsAg                                                                                                            
  Negative                       32         22 (68.8)                                          1.00                
  Positive                       239        163 (68.2)                                         1.00 (0.64--1.56)   0.987
  Smoking                                                                                                          
  Never                          175        120 (68.6)                                         1.00                
  Ever                           96         65 (67.7)                                          1.11 (0.82--1.50)   0.503
  Drinking                                                                                                         
  Never                          173        118 (68.2)                                         1.00                
  Ever                           98         67 (68.4)                                          1.09 (0.81--1.47)   0.587
  Intact capsule                                                                                                   
  No                             226        152 (67.3)                                         1.00                
  Yes                            45         33 (73.3)                                          1.11 (0.77--1.62)   0.573
  Portal vein tumor thrombosis                                                                                     
  No                             214        139 (65)                                           1.00                
  Yes                            57         46 (80.7)                                          1.59 (1.13--2.22)   0.007
  Cirrhosis                                                                                                        
  No                             98         75 (76.5)                                          1.00                
  Yes                            173        110 (63.6)                                         0.72 (0.54--0.97)   0.030
  BCLC staging                                                                                                     
  0/A                            86         50 (58.1)                                          1.00                
  B/C                            176        128 (72.7)                                         1.62 (1.17--2.25)   0.004
  Missing                        9                                                                                 

HCC, hepatocellular carcinoma; DFS, disease‐free survival; HRs, hazards ratio; CI, confidence interval; HBsAg, hepatitis B virus surface antigens; BCLC, Barcelona Clinic Liver Cancer.

Including relapse, metastasis and death.
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Survival analysis of SNPs and DFS {#cam41067-sec-0009}
---------------------------------

As shown in Table [3](#cam41067-tbl-0003){ref-type="table-wrap"}, 16 SNPs were genotyped successfully in all HCC patients, while the other eight SNPs had a few missing data. Because *ORC6L* rs12596237 had only one single genotype, we included 23 SNPs for further analysis. We first performed Cox proportional hazards regression analysis to assess associations of individual SNPs in genes of the cell cycle pathway with DFS. We found that four SNPs were significantly associated with DFS at *P *\<* *0.05 under an additive genetic model, of which three SNPs, i.e. rs11556090 (*P *=* *0.004, FPRP = 0.03), rs8025774 (*P *=* *0.020, FPRP = 0.15) and rs3929 (*P *=* *0.023, FPRP = 0.17), had FPRP \<0.2. To assess the independent prognostic factor of DFS, we further conducted stepwise Cox regression analysis by including the clinical variables and the significant SNPs. The results demonstrated that BCLC staging, *SMAD3* rs11556090, and *RBL2* rs3929 were still significantly associated with DFS of HCC patients (Table [4](#cam41067-tbl-0004){ref-type="table-wrap"}). Taken all together, we selected *SMAD3* rs11556090 A\>G and *RBL2* rs3929G\>C as the final independent SNPs for further analyses. The identified SNPs were both predicted to be in the miRNA‐binding sites (Table [1](#cam41067-tbl-0001){ref-type="table-wrap"}), which may affect the binding capacity of miRNA and the corresponding gene. As shown in Table [5](#cam41067-tbl-0005){ref-type="table-wrap"}, our results demonstrated that the *SMAD3* rs11556090G allele was significantly associated with a shorter DFS (trend test: *P *=* *0.004), while the *RBL2* rs3929 C allele was associated with a superior DFS (trend test: *P *=* *0.023). Similarly, the *SMAD3* rs11556090 GG+GC genotypes were associated with a shorter DFS, compared with the CC genotype (HR = 1.54, 95% CI = 1.13--2.09, *P *=* *0.006), and similar results were found for the *RBL2* rs3929 CC+GC genotypes, compared with the GG genotype (HR = 4.98, 95% CI = 1.57--15.83, *P *=* *0.006). For the visual effect, we used Kaplan--Meier curves to depict associations between the significant SNPs and DFS (Fig. [1](#cam41067-fig-0001){ref-type="fig"}A--D).

###### 

Association between SNPs of cell cycle pathway genes and HCC DFS by multivariate Cox proportional hazards regression model

  SNP          Gene       Allele[a](#cam41067-note-0010){ref-type="fn"}   Frequency of genotypes (%)   Missing      DFS                                               
  ------------ ---------- ----------------------------------------------- ---------------------------- ------------ ----------- --------- ------------------- ------- ------
  rs3734166    *CDC25C*   A/G                                             108 (39.9)                   136 (50.2)   27 (10)     --        0.92 (0.73--1.16)   0.460   0.81
  rs13447539   *CDC7*     A/G                                             260 (95.9)                   11 (4.1)     --          --        0.69 (0.28--1.73)   0.433   0.84
  rs3176320    *CDKN1A*   A/G                                             145 (53.5)                   112 (41.3)   14 (5.2)    --        0.91 (0.70--1.17)   0.445   0.80
  rs3176329    *CDKN1A*   G/T                                             177 (65.3)                   73 (26.9)    7 (2.6)     4 (1.5)   1.12 (0.83--1.50)   0.466   0.81
  rs3088440    *CDKN2A*   G/A                                             193 (71.2)                   73 (26.9)    5 (1.8)     --        0.86 (0.63--1.19)   0.370   0.77
  rs3731399    *CHEK1*    T/C                                             206 (76.0)                   59 (21.8)    5 (1.8)     1 (0.4)   1.22 (0.89--1.68)   0.224   0.67
  rs515255     *CHEK1*    C/T                                             106 (39.1)                   129 (47.6)   31 (11.4)   5 (1.8)   1.01 (0.81--1.26)   0.938   0.89
  rs2305952    *MCM4*     T/C                                             195 (72.0)                   74 (27.3)    2 (0.7)     --        1.02 (0.74--1.41)   0.917   0.89
  rs2070215    *MCM7*     A/G                                             123 (45.4)                   110 (40.6)   38 (14)     --        1.08 (0.88--1.33)   0.464   0.81
  rs2261360    *MCM7*     C/A                                             117 (43.2)                   111 (41.0)   42 (15.5)   1 (0.4)   0.99 (0.80--1.22)   0.910   0.89
  rs4928       *MCM7*     C/G                                             243 (89.7)                   27 (10.0)    1 (0.4)     --        0.93 (0.57--1.54)   0.782   0.88
  rs4645948    *MYC*      C/T                                             192 (70.8)                   74 (27.3)    5 (1.8)     --        0.95 (0.70--1.30)   0.744   0.87
  rs12596237   *ORC6L*    C/T                                             271 (100)                    --           --          --        --                  --      --
  rs33994299   *ORC6L*    T/C                                             254 (93.7)                   16 (5.9)     --          1 (0.4)   0.44 (0.21--0.96)   0.039   0.48
  rs17006625   *PCAF*     A/G                                             153 (56.5)                   100 (36.9)   18 (6.6)    --        1.03 (0.81--1.30)   0.823   0.88
  rs4858770    *PCAF*     C/T                                             99 (36.5)                    130 (48.0)   38 (14.0)   4 (1.5)   0.98 (0.77--1.24)   0.861   0.89
  rs2230915    *PLK1*     G/A                                             251 (92.6)                   19 (7.0)     1 (0.4)     --        1.09 (0.65--1.83)   0.742   0.87
  rs16889105   *RAD21*    A/G                                             114 (42.1)                   112 (41.3)   45 (16.6)   --        1.17 (0.94--1.45)   0.157   0.59
  rs6987652    *RAD21*    G/A                                             199 (73.4)                   66 (24.4)    6 (2.2)     --        0.88 (0.65--1.21)   0.438   0.80
  rs3929       *RBL2*     G/C                                             160 (59.0)                   95 (35.1)    14 (5.2)    2 (0.7)   0.74 (0.57--0.96)   0.023   0.17
  rs11556090   *SMAD3*    A/G                                             162 (59.8)                   98 (36.2)    11 (4.1)    --        1.46 (1.13--1.89)   0.004   0.03
  rs8025774    *SMAD3*    C/T                                             79 (29.2)                    141 (52.0)   50 (18.5)   1 (0.4)   0.76 (0.61--0.96)   0.020   0.15
  rs3917148    *TGFB3*    A/C                                             212 (78.2)                   56 (20.7)    2 (0.7)     1 (0.4)   0.97 (0.69--1.38)   0.872   0.89
  rs2425675    *YWHAB*    G/A                                             173 (63.8)                   88 (32.5)    10 (3.7)    --        1.01 (0.77--1.33)   0.919   0.89

SNP, single‐nucleotide polymorphism; HCC, hepatocellular carcinoma; DFS, disease‐free survival; MhoG, major homozygous genotype; HetG, heterozygous genotype; RhoG, rare homozygous genotype; HR, hazards ratio; CI, confidence interval; FPRP, false positive report probability.

Reference allele/minor allele.

Adjusted by age, sex, ethnicity, HBsAg status, smoking status, drinking status, intact capsule, portal vein tumor thrombosis, cirrhosis and BCLC staging.
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###### 

Predictors of DFS obtained from stepwise Cox proportional hazards regression analysis

  Parameter      Parameter estimate   Standard error   Chi‐square   HR (95% CI)[a](#cam41067-note-0013){ref-type="fn"}   *P* [a](#cam41067-note-0013){ref-type="fn"}
  -------------- -------------------- ---------------- ------------ ---------------------------------------------------- ---------------------------------------------
  Age            −0.11                0.16             0.45         0.90 (0.66--1.22)                                    0.501
  Sex            0.02                 0.25             0.01         1.02 (0.63--1.67)                                    0.930
  Ethnicity      −0.13                0.15             0.77         0.88 (0.65--1.18)                                    0.380
  BCLC staging   0.45                 0.14             9.73         1.57 (1.18--2.08)                                    0.002
  rs3929         −0.27                0.13             4.39         0.76 (0.59--0.98)                                    0.036
  rs11556090     0.30                 0.13             5.49         1.36 (1.05--1.75)                                    0.019

DFS, disease‐free survival; HR, hazards ratio; CI, confidence interval; BCLC, Barcelona Clinic Liver Cancer.

Stepwise analysis included sex, age, ethnicity, HBsAg status, smoking status, drinking status, intact capsule, portal vein tumor thrombosis, cirrhosis, BCLC staging, *RBL2* rs3929, *SMAD3* rs8025774, and *SMAD3* rs11556090.
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###### 

Association of *SMAD3* rs11556090 and *RBL2* rs3929 with DFS of HCC patients

  Genotypes                                                  Patients   Events (%)[a](#cam41067-note-0015){ref-type="fn"}   Univariate analysis   Multivariate analysis[b](#cam41067-note-0016){ref-type="fn"}                       
  ---------------------------------------------------------- ---------- --------------------------------------------------- --------------------- -------------------------------------------------------------- ------------------- -------
  *SMAD3* rs11556090                                                                                                                                                                                                                 
  AA                                                         162        103 (63.6)                                          1                                                                                    1                   
  AG                                                         98         73 (74.5)                                           1.42 (1.05--1.92)     0.021                                                          1.50 (1.09--2.06)   0.013
  GG                                                         11         9 (81.8)                                            1.45 (0.73--2.86)     0.289                                                          2.00 (0.98--4.05)   0.056
  Trend test                                                                                                                                      0.017                                                                              0.004
  AA                                                         162        103 (63.6)                                          1                                                                                    1                   
  AG+GG                                                      109        82 (75.2)                                           1.32 (1.04--1.67)     0.023                                                          1.54 (1.13--2.09)   0.006
  *RBL2 rs3929*                                                                                                                                                                                                                      
  GG                                                         160        114 (71.3)                                          1                                                                                    1                   
  GC                                                         95         67 (70.5)                                           0.91 (0.68--1.24)     0.554                                                          0.94 (0.68--1.29)   0.696
  CC                                                         14         3 (21.4)                                            0.18 (0.06--0.57)     0.004                                                          0.20 (0.06--0.63)   0.006
  Trend test                                                                                                                                      0.009                                                                              0.023
  CC                                                         14         3 (21.4)                                            1                                                                                    1                   
  GG+GC                                                      255        181 (71.0)                                          5.31 (1.7--16.6)      0.004                                                          4.98 (1.57−15.83)   0.006
  Combined analysis[c](#cam41067-note-0017){ref-type="fn"}                                                                                                                                                                           
  0 NUGs                                                     12         3 (25.0)                                            1                                                                                    1                   
  1 NUG                                                      151        99 (65.6)                                           3.79 (1.20−11.96)     0.023                                                          3.53 (1.10−11.36)   0.034
  2 NUGs                                                     106        82 (77.4)                                           5.42 (1.71−17.17)     0.004                                                          5.46 (1.70−17.58)   0.004
  Trend test                                                            0.0003                                                                    0.0001                                                                             

DFS, disease‐free survival; HCC, hepatocellular carcinoma; HR, hazards ratio; CI, confidence interval; NUG, number of unfavorable genotypes.

Including relapse, metastasis and death.

Adjusted by age, sex, ethnicity, HBsAg status, smoking status, drinking status, intact capsule, hepatic vein tumor thrombosis, cirrhosis and BCLC staging.

Unfavorable genotypes were *SMAD3* rs11556090 AG+GG and *RBL2* rs3929 GG+GC.
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![*SMAD3* rs11556090 and *RBL2* rs3929 associated with disease‐free survival of hepatocellular carcinoma patients. (A--D) Kaplan--Meier survival curves of single nucleotide polymorphisms in different genetic models: rs11556090 in an additive genetic model (A) and dominant model (B); rs3929 in an additive genetic model (C) and recessive model (D). (E) Kaplan--Meier survival curves of combined effects of the unfavorable genotypes. (F) Receiver operating characteristic (ROC) curve and area under the curve (AUC) estimation for prediction of 1‐year DFS.](CAM4-6-1512-g001){#cam41067-fig-0001}

Combined effects and ROC curves for DFS prediction {#cam41067-sec-0010}
--------------------------------------------------

To evaluate the joint effect of *SMAD3* rs11556090 and *RBL2* rs3929, we combined risk genotypes of rs11556090 CC and rs3929GG+GC into a single variable as the number of unfavorable genotypes (NUGs) (Table [5](#cam41067-tbl-0005){ref-type="table-wrap"}). The trend test indicated that increased NUG was associated with a shorter DFS regardless of univariate (trend test: *P *=* *0.0003) or multivariate analysis (trend test: *P *=* *0.0001). The Kaplan--Meier curves for depicting associations between NUG and DFS is also shown in Figure [1](#cam41067-fig-0001){ref-type="fig"}E. Using the ROC curves, we further evaluated predictive value of the unfavorable genotypes. The results demonstrated that, as classification of 1‐year DFS, the AUC was significantly increased from 68.4% to 74.1% (*P *=* *0.011), when adding NUG to the model including clinical variables (age, sex, ethnic, hepatitis B virus infection, smoking status, drinking status, capsule, portal vein tumor thrombosis, cirrhosis and BCLC staging) as classifiers (Fig. [1](#cam41067-fig-0001){ref-type="fig"}F).

*In silico* functional validation {#cam41067-sec-0011}
---------------------------------

As mapped on the UCSC website (<https://genome.ucsc.edu/>), rs11556090 is located in exon 9, 3ʹUTR of *SMAD3*, while rs3929 is located in exon 22, 3ʹUTR of *RBL2* (Fig. [2](#cam41067-fig-0002){ref-type="fig"}A and B). Both of them were predicted to be miRNA binding sites of the corresponding genes by the SNPinfo. We further conducted the expression quantitative trait loci (eQTL) analysis by searching on the GTEx Portal (<http://www.gtexportal.org/home/>) and using data from the 1000 Genomes Project to examine the effects of SNPs on the mRNA expression levels of corresponding genes. We only found information about *RBL2* on GTEx Portal that the rs3929 C allele was significantly associated with increased expression levels of *RBL2* in liver tissues (*P *=* *1.8 × 10^−7^, Fig. [2](#cam41067-fig-0002){ref-type="fig"}C) and the whole blood (*P *=* *3.9 × 10^−14^, Fig. [2](#cam41067-fig-0002){ref-type="fig"}D) by general linear regression analysis. Data of Asian population (the Chinese and Japanese together) from the HapMap 3 Project showed no significant association for neither rs11556090 nor rs3929 with their corresponding gene expression levels (*P *=* *0.486 and 0.686, respectively, Fig. [2](#cam41067-fig-0002){ref-type="fig"}E and F).

![In *silico* functional validation of *SMAD3* rs11556090 and *RBL2* rs3929. Location‐map of rs11556090 (A) and rs3929 (B) in UCSC website (<https://genome.ucsc.edu/>); The expression quantitative trait loci analysis (eQTL) from the GTEx Portal (<http://www.gtexportal.org/home/>) for *RBL2* rs3929 in liver tissue (C) and the whole blood (D); eQTL analysis by using Asian population of HapMap3 data for rs11556090 (E) and rs3929 (F).](CAM4-6-1512-g002){#cam41067-fig-0002}

Discussion {#cam41067-sec-0012}
==========

In this hypothesis‐driven study, we identified *SMAD3* rs11556090 A\>G and *RBL2* rs3929 G\>C in the cell cycle pathway may independently or jointly modulate DFS of HCC patients. We also observed that combining with unfavorable genotypes of these loci significantly improved prediction performance of HCC survival in the model that included the known clinical prognostic variables. Furthermore, the results from the GTEx Portal demonstrated that the C allele was significantly associated with increasing expression levels of *RBL2*, suggesting that *RBL2* rs3929 may modulate DFS of HCC patients possibly through a mechanism of modulating gene expression.

Cell cycle control is an important process for DNA damage repair. When DNA damage occurs, cell cycle checkpoints are activated and cell cycle progression is paused, allowing cells sufficient time to repair the damage and determining whether cells will survive or die, which is controlled by the cell cycle pathway players [21](#cam41067-bib-0021){ref-type="ref"}. Previous studies have shown that the identified genes, *SMAD3* and *RBL2*, are important players in the cell cycle control. For example, *SMAD3* plays a critical part in the regulation of transforming growth factor‐β (TGF‐β), which is a potent inhibitor of cell cycle progression at the G1 phase [37](#cam41067-bib-0037){ref-type="ref"}. Likewise, *RBL2*, encoding one of the retinoblastoma family proteins (RBL2, also known as p130 and pRb2), is a key switch at the restriction point (R) and inhibits the S phase entry by physical combination with E2F transcription factor and actively represses gene transcription that regulates DNA synthesis in the S phase [38](#cam41067-bib-0038){ref-type="ref"}. Other studies reported that *SMAD3* functioned as a tumor suppressor in cancers of the stomach, [39](#cam41067-bib-0039){ref-type="ref"}, breast [40](#cam41067-bib-0040){ref-type="ref"} and prostate [41](#cam41067-bib-0041){ref-type="ref"}, while *RBL2* functions as a tumor suppressor in cancers of the breasts, ovaries and endometrium [42](#cam41067-bib-0042){ref-type="ref"}. A similar function in HCC has also been illustrated for both of *SMAD3* and *RBL2* in the previous studies [43](#cam41067-bib-0043){ref-type="ref"}, [44](#cam41067-bib-0044){ref-type="ref"}, suggesting the significant function of *SMAD3* and *RBL2* as a tumor suppressor in HCC.

In this study, both of the two loci we identified were computationally predicted to be located in the microRNA‐binding sites by the SNPinfo. *SMAD3* rs11556090 is located in the binding site of hsa‐miR‐132, hsa‐miR‐188, hsa‐miR‐212, hsa‐miR‐30b, hsa‐miR‐337, hsa‐miR‐431, hsa‐miR‐532 and hsa‐miR‐9, while *RBL2* rs3929 was located only in has‐miR‐134. Surprisingly, the above‐mentioned miRNAs, except for has‐miR‐337 and has‐miR‐532, have been associated with development or survival of HCC [45](#cam41067-bib-0045){ref-type="ref"}, [46](#cam41067-bib-0046){ref-type="ref"}, [47](#cam41067-bib-0047){ref-type="ref"}, [48](#cam41067-bib-0048){ref-type="ref"}, [49](#cam41067-bib-0049){ref-type="ref"}, [50](#cam41067-bib-0050){ref-type="ref"}, [51](#cam41067-bib-0051){ref-type="ref"}. Therefore, it is likely that the underlying mechanisms of the two SNPs in modulating HCC survival are to regulate the transcription of proteins by affecting activities of miRNA‐binding. SNPs in the potential miRNA‐binding sites are suggested to be functional and always good candidates for causal variants of human disease occurrence or progress [52](#cam41067-bib-0052){ref-type="ref"}. Specifically, we found that the *RBL2* rs3929 C allele associated with a longer DFS was correlated with increased mRNA expression levels of *RBL2* in normal liver tissues and peripheral blood lymphocytes by using data from the GTEx Portal. These results are consistent with the characteristics of a tumor suppressor, although the majority of the donors for the GTEx project are of the white population. However, somatic mutations in *RBL2* were observed previously only in primary nasopharyngeal carcinomas, lung tumors, and Burkitt\'s lymphomas but not in HCC. Taken together, we can infer that *RBL2* rs3929 may be a functional and important variant for HCC progression.

The results also demonstrated a significant locus‐dosage effect in patients with a larger number of unfavorable genotypes, who had a shorter DFS, suggesting an interaction of *SMAD3* rs11556090 and *RBL2* rs3929 in the cell cycle pathway on HCC progress. The potential mechanism under the observed association is probably that both of SMAD3 and RBL2 are the key substrates of CDK4, which can control cell cycle progression from the G1 to S phase by phosphorylation of these proteins [37](#cam41067-bib-0037){ref-type="ref"}, [53](#cam41067-bib-0053){ref-type="ref"}. Importantly, The combination of the two loci significantly improved prediction performance of the model that included the known prognosis factors of HCC patients.

It should be noted that there were limitations of this study. The first limitation included restriction of the recruit population. We conducted the study only in the population from Guangxi Zhuang Autonomous Region, where the main cause of HCC is HBV infection [28](#cam41067-bib-0028){ref-type="ref"}. The results may not apply to other ethnic groups or disease etiologies, such as hepatitis C virus infection, nonalcoholic fatty liver disease and alcoholic liver disease. Secondly, the significance of *RBL2* rs3929 and *SMAD3* rs11556090 in the prognosis of HCC has been demonstrated in this study, however, it still lack epidemiology validation and biological mechanism confirmation, besides the significant eQTL results for *RBL3* rs3929 from the GTEx project. Finally, because of lack of more detailed clinical information, we did not efficiently evaluated the potential effects of different therapies after radical surgery resection on the outcomes of HCC patients, or their potential associations with the identified SNPs. Therefore, larger scale, more comprehensive and multi‐institutional epidemiology investigations and biological studies are warranted to further validate these results.

In conclusion, this study identified a prognostic role of *SMAD3* rs11556090 and *RBL2* rs3929 of the cell cycle pathway in HCC patients. Although both of *SMAD3* and *RBL2* are important in the control of cell cycle progression from the G1 to S phase, the interpretation of our findings should be cautious, until validated by mort patient cohorts and HCC cell lines.
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